Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elironrasib and daraxonrasib dose-escalation/expansion study in advanced KRAS G12C-mutated solid tumors
NL-OMON60543Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- Jul 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elironrasib and daraxonrasib in Nonhematologic neoplasms (3 arms), sponsored by Revolution Medicines. Started Jul 2024; status: recruiting.
02
Drugs
elironrasibdaraxonrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60543.